Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 127Neoplasm Metastasis 14Neoplasms 9Advanced Breast Cancer 6Endometrial Neoplasms 5Recurrence 4Hereditary Sensory and Autonomic Neuropathies 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Ovarian Neoplasms 3Neoplasms, Hormone-Dependent 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Lobular 3Carcinoma, Ductal, Breast 3Squamous Cell Carcinoma of Head and Neck 2Polycystic Ovary Syndrome 2Osteoporosis 2Neoplasms by Site 2Lymphoma, Non-Hodgkin 2Head and Neck Neoplasms 2HR+/HER2- Breast Cancer 2Breast Neoplasms, Male 2Breast Diseases 2Bone Diseases, Metabolic 2Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Small Cell Lung Carcinoma 1Osteitis Deformans 1Multiple Endocrine Neoplasia Type 1 1Mesothelioma, Malignant 1

Interventions

palbociclib 1Letrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Breast Cancer (Female) × Letrozole × Clear all
NCT02142868 2018-12-21

Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

Pfizer

No longer available
Breast

Advanced Breast Cancer (Female)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡